Executive Summary
EiRx Therapeutics (LSE: ERX) is a research-driven healthcare company developing new targeted therapies for the treatment of cancer. The company, which is headquartered in Cork, Ireland, conducts drug discovery from its laboratories in Cork and in Aberdeen, Scotland, and has an initial focus on colorectal tumours, currently the number two cause of cancer-related deaths world-wide. Since its foundation in 1999 EiRx has developed into a leader in the study of functional pathways critical to cancer cell survival and growth, with a research base encompassing apoptosis biology, translational medicine and the metabolic basis of drug resistance in tumours. Using its state-of-the-art, proprietary ALIBITM platform, EiRx has gained new insights into the mechanisms underlying a cell's decision to survive or die, and has implicated a range of novel genes in pivotal control mechanisms such as the PI3K/AKT and GSK/Wnt survival pathways. In combining functional validation technologies with unique clinical resources such as the ACCRI-BANK tissue collection, EiRx is linking the molecular activity of these targets with clinical consequences in patient populations. By streaming validated targets into an innovative compound screening approach EiRx is creating a product development engine specialising in cancer target discovery, validation and targeted therapy. The EiRx business strategy is three-fold, and integrates (i) discovery and out-licensing of validated cancer diagnostic and drug targets, (ii) discovery and development of new anticancer drugs through independent or collaborative research, and (iii) application of proprietary knowledge and technologies through collaborative R&D initiatives.
Company History
Current Events
Business Model
Products/Services
Segments/Customers
Production/Operations
Distribution/Routes to Market
Market & Competition
Market Share
Main Competitors
Competitive Strengths and Weaknesses
Management
Financials
Profit & Loss
Balance sheet
Cashflow
Valuation
Comparable Companies
SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
